RATIONALE FOR APPLICATION, AND BENEFITS OF TRIMETAZIDINE IN HEART FAILURE BY ITS INFLUENCE OF MYOCARDIUM METABOLISM

• Main Authors: Yu. M. Lopatin, Giuseppe M.K. Rosano, Gabriel Fragasso, Gari D. Lopashchuk, Petar M. Seferovich, Louis Henrique V. Goudac, Dragos Vinereanu, Magdi Abdel Hamid, Patric Jourdain, Petr Ponikovsky
• Format: Article
• Language: Russian
• Published: «FIRMA «SILICEA» LLC 2016-08-01
• Series: Российский кардиологический журнал
• Subjects: heart failure; energetic metabolism of the heart; trimetazidine
• Online Access: https://russjcardiol.elpub.ru/jour/article/view/890
• ISSN: 1560-4071; 2618-7620

Heart failure (HF) is systemic and multiple organ syndrome, with metabolic insufficiency as one of its main causes. Heart metabolism disorders in HF activate other processes that futher worsens progression of the disease. Recent data shows that correction of energy metabolism in the heart by suppression of fatty acids (FA) oxydation and/or increase of glucose oxydation is one of promising approaches in HF patient’s treatment. Clinical studies showed that addition of trimetazidine to standard medication therapy improves sympthoms, cardiac function and prognosis in HF patients, not influencing negatively hemodynamics. The review is focused on rationale for and clinical benefits of trimetazidine application according to its influence on myocardial metabolism in HF. Also a very high level of preparedness of the drug to inclusion into main guidelines on HF is pointed on.